This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA217427; GEO: GSE50410 |
| Type | Umbrella project |
| Submission | Registration date: 28-Aug-2013
NCI |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| GEO DataSets | 9 |
GEO Data Details| Parameter | Value |
|---|
| Data volume, Spots | 122260 |
| Data volume, Processed Mbytes | 8 |
| Data volume, Supplementary Mbytes | 178 |
This project encompasses the following 8 sub-projects:
| Project Type | Number of Projects |
| Proteome | 8 |
BioProject
accession | Organism | Title |
|---|
| PRJNA217428 | Homo sapiens | Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217429 | Homo sapiens | Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200) (NCI) | | PRJNA217430 | Homo sapiens | Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200) (NCI) | | PRJNA217431 | Homo sapiens | Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217432 | Homo sapiens | Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) |
List all 8 'Proteome' projects...BioProject
accession | Organism | Title |
|---|
| PRJNA217428 | Homo sapiens | Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217429 | Homo sapiens | Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200) (NCI) | | PRJNA217430 | Homo sapiens | Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200) (NCI) | | PRJNA217431 | Homo sapiens | Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217432 | Homo sapiens | Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217433 | Homo sapiens | Post-vaccination serum anti-glycan IgG antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217434 | Homo sapiens | Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) | | PRJNA217435 | Homo sapiens | Post-vaccination serum anti-glycan IgM antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50) (NCI) |
Less... |